Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1. 系统已在2025-03-07 16:56:14对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1021/acs.jmedchem.4c02313
文献链接: https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02313
其他信息:
出版社: American Chemical Society (ACS)
作者: James Cregg; Kristof Pota; Aidan C. A. Tomlinson; Jason Yano; Abby Marquez; Yang Liu; Christopher J. Schulze; Kyle J. Seamon; Matthew Holderfield; Xing Wei; Yongxian Zhuang; Yu Chi Yang; Jingjing Jiang; Yue Huang; Ruiping Zhao; Yun Ling; Zhican Wang; Michael Flagella; Zhengping Wang; Mallika Singh; John E. Knox; Robert Nichols; David Wildes; Jacqueline A. M. Smith; Elena S. Koltun; Adrian L. Gill
全文下载地址: https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c02313
